Regeneron Pharmaceuticals Inc. (REGN)

298.11
NASDAQ : Health Technology
Prev Close 303.09
Day Low/High 296.35 / 303.68
52 Wk Low/High 287.66 / 442.00
Avg Volume 859.20K
Exchange NASDAQ
Shares Outstanding 107.73M
Market Cap 33.23B
EPS 22.60
P/E Ratio 14.35
Div & Yield N.A. (N.A)

The Next Biotech Breakout?

As always, I am happy to be standing in for Doug Kass today on the Daily Diary (this Friday from sunny Miami). It looks like it will be an up open to talk about based on early market futures. The euro is heading towards its best week in 18 months, e...

These Stocks Get Benefit of the Doubt

Market backtracks on skepticism over biotechs.

Remarkable Biotech Runs Continue

A Fed-related dip may be your only hope to get in lower.

What Is Wrong With You People?

These companies are doing great -- take some profits!

Blame It (or Much of It) on the Dollar

What if you make a move and the Fed wrecks it?

2 Biotechs That Still Offer Value

2 Biotechs That Still Offer Value

Amgen and Gilead shine in one of the market's best-performing sectors.

Market Rewards Biotech Latecomers

It shouldn't be possible, but it never seems too late to get in.

That's Just What's Supposed to Happen

Stocks that stabilized yesterday were terrific today.

The Biotechs Are Feeling Better

Sector could regain its leadership role.

The Biotechs Are Back

Watch this leadership group that's been lagging.

Violent Moves in a 'Scarface' Market

The 'dead bodies' are adding up.

8 Signs the Market Is Remarkably Healthy

These are surefire indications of a bountiful tape.

A Tasty Reversal With 6 Key Ingredients

But tomorrow we hear from the banks.

Braving Biotech

Do you need to pick one name? Biotech has carried with it a lasting resiliency like few other sectors. Perhaps it is driven by optimism and hope. Perhaps it is driven by the fear of suffering or watching someone suffer from the very illnesses these ...

Regeneron upgraded at Morgan Stanley

Go With What's Worked, Part 1

Throughout this historic run, four groups have consistently led the market.

Absolutely Nothing Happened

There had been no catalysts.

Cramer: Oil-and-Gas vs. Everything Else

Reams of stocks make sense on a pullback. And what looks bad? Anything even remotely connected to oil and gas.

There's a Lot Going on Under the Hood

An immense market rotation is happening.

'Top Fishing' Is the Name of the Game

Stocks, like sports, are unfair sometimes. This is one of those times.

It Doesn't Stop

The end-of-the-year phenomenon is working.

You Have to Love Biotech

In this era of turmoil, investors can take comfort in this sector.

Here's Your Thesis to Buy

This market provides a slew of reasons to buy right now.

The Hazards of Skepticism

In this market, negativity is rarely being rewarded.

Their Weakness Is Our Strength

The U.S. markets and economy are unique.

Growth Seekers Return

Investors are seeing growth today in three areas.

How Bad Was (Fill in the Blank)?

Let's play a game.

Don't Expect Any Apologies

Still, it's a good time to review what's happening, so we never forget.

How to Game This Clueless Market

As long as you use common sense, you will be able to profit.

Leadership Is Back

Welcome back to the airlines and the biotechs.